A newly published two-part scientific study raises major alarms about an issue that has received remarkably little scrutiny: What happens when blood from COVID-19-vaccinated donors is transfused into another person?
Blood banks routinely screen donations for recognized infectious threats. Yet the current blood supply is not routinely screened for vaccine-derived mRNA, spike protein, plasmid DNA, amyloid, fibrin-microclot complexes, or other relevant vaccine-associated constituents.
Our newly published two-part series investigates this blind spot from two complementary directions. The two studies were authored by James A. Thorp, MD; Claire Rogers, MSPAS, PA-C; R. Clinton Ohlers, PhD; M. Nathaniel Mead, PhD; Nicolas Hulscher, MPH (myself); Kirstin Cosgrove, CCRA; Sierra Hamm, RN; David Speicher, PhD; and Steven Hatfill, MD, M Med.
Part I presents a retrospective, hypothesis-generating case series of nine individuals who had not received a COVID-19 vaccine and subsequently experienced serious medical events after receiving blood transfusions.
Reported complications included thromboembolic disease, progressive clotting disorders, myocarditis, pericardial disease, disseminated intravascular coagulation, multi-organ system failure, and death.
We concluded that these cases, together with the existing literature, raise sufficient concern to warrant direct investigation of whether biologically active vaccine-derived constituents may be present in donated blood:
This study suggests that blood donated by COVID-19-vaccinated individuals may contain biologically active vaccine-derived constituents that could cause adverse clinical outcomes. The case reports and cited studies identify questions that warrant further investigation. All the pathogenic components of the COVID-19 vaccine or byproducts from it, have been found in several studies to be circulating in the blood of vaccinated donors. Healthcare providers must honor the ethical principles of patient autonomy and non-maleficence and support patients’ requests for autologous and directed designated donor blood. Screening blood donations for the presence of spike protein, amyloid, fibrin-microclot complexes, vaccine-derived mRNA, and plasmid DNA using quantitative assays and PCR-based methods should be considered for further evaluation by relevant public health and regulatory authorities, including the CDC and FDA.
Hellbound and Down 